Home Symposium | About | Program | Registration | Contact | Venue | 2021 | 2019 | 2017 | 2015
Program
5th Duesseldorf-Juelich Symposium on Neurodegenerative Diseases: "Amyloid, from early aggregation steps to clinical trials and new concepts" will take place from 5 to 7 December 2023 in Duesseldorf, Germany.
There will be talks on the following topics:
- Anti-amyloid antibody trials, outcome, meaningfulness, treatment costs, etc.
- Biomarkers and amyloid clearance
- Basic science: amyloid structures and early aggregation steps incl. LLPS
- New concepts in therapy
Preliminary Program 2023
Tuesday, December 5, 2023
09:15 | Registration |
09:30 | WELCOME Inga Kadish (organizing comittee) Heersink School of Medicine, Dept. Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, USA |
09:35 | Welcome addresses NN (Heinrich Heine University Düsseldorf, Germany) NN (Forschungszentrum Jülich GmbH, Germany) Michael Lorrain, Chairman Alzheimer Forschung Initiative e.V., Düsseldorf, Germany |
SESSION I: Anti-amyloid antibody trials, outcome, meaningfulness and treatment costs | |
09:45 | Neurobiology of Alzheimer disease in people with Down syndrome Elizabeth Head Department of Pathology and Laboratory Medicine, University of California, Irvine, |
10:35 | Coffee break |
11:00 | Lutz Frölich and Lucretia Hausner Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit |
11:50 | Towards a future where Alzheimer’s disease is stopped before onset of dementia Wiesje van der Flier Alzheimer Centre, Department of Neurology, Amsterdam Neuroscience, |
12:40 | NN Talk by early career scientist (selected from the poster abstracts submitted) |
13:00 | Lunch break |
13:50 | Key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD) Frank Boess F. Hoffmann-La Roche Ltd., Product Development Neuroscience, Basel, Switzerland |
SESSION II: New concepts in therapy | |
14:40 | NN Talk by early career scientist (selected from the poster abstracts submitted) |
15:00 | Vaccination with modified fungal proteins mimicking conformational epitopes on alpha-synuclein fibrils prolongs survival in mouse models of Parkinson's disease Erdem Tamgüneya and Holger Willeb aInstitut für Physikalische Biologie, Heinrich Heine University Düsseldorf and Forschungszentrum Jülich, IBI-7: Structural Biochemistry, Jülich, Germany bCentre for Prions and Protein Folding Diseases & Department of Biochemistry, |
15:50 | Antje Willuweit Priavoid GmbH, Düsseldorf, Germany and Institute of Neuroscience and Medicine |
16:40 | NN Talk by early career scientist (selected from the poster abstracts submitted) |
17:00 | Break |
PUBLIC SCIENCE LECTURE | |
18:15 | Gemeinsam gegen das Vergessen: Informationsabend zu neuen Alzheimer-Therapien Frank Jessen Department of Psychiatry, Medical Faculty University of Cologne and German Center |
Wednesday, December 6, 2023
SESSION III: Biomarkers and amyloid clearance | |
09:30 | How fluid biomarkers revolutionize the diagnosis of Alzheimer´s disease Oliver Peters Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin and German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany |
10:20 | NN Talk by early career scientist (selected from the poster abstracts submitted) |
10:40 | Coffee break |
11:00 | Stage 2 of AD as a target for DMT treatment Frank Jessen Department of Psychiatry, Medical Faculty University of Cologne and German Center |
11:50 | Oligomers count Oliver Bannach attyloid GmbH, Düsseldorf, Germany and Forschungszentrum Jülich, IBI-7: Structural Biochemistry, Jülich, Germany |
12:40 | Lunch break |
SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS | |
13:30 | Exploiting cross-amyloid interactions to design inhibitors of amyloid self-assembly Aphrodite Kapurniotu Division of Peptide Biochemistry, TUM School of Life Sciences, Technical University of Munich (TUM), Freising, Germany. |
14:20 | Flash Talks 15 poster presenters, 1 min time per talk. |
14:40 | Phase transitions of Tau: how liquid condensates catalyze pathological aggregation Susanne Wegmann German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany |
15:30 | Flash Talks, 15 poster presenters, 1 min time per talk. |
15:50 | Funding Opportunities: Alzheimer Forschung Initiative e.V. (AFI) Jochen Walter Klinik für Neurologie, Universitätsklinikum Bonn, Germany |
POSTER SESSION | |
16:00 | Poster session with guided poster tours and finger food buffet |
Thursday, December 7, 2023
SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS | |
09:30 | Structure dynamics of human PLCγ2 in auto-inhibition Julie Chen and John Wang Eisai, Center for Genetics Guided Dementia Discovery, Cambridge, Massacusetts, USA |
10:20 | NN Talk by early career scientist (selected from the poster abstracts submitted) |
CV – BEHIND THE SCENES | |
10:40 | CV – behind the scenes Four presentations by invited speakers 15 min each. The speakers report on their personal journey in academic or industrial research. |
11:40 | Lunch break |
SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS | |
12:10 | Sjors Scheres MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK |
13:00 | Structures and mechanisms of formation of amyloid-beta assemblies Robert Tycko Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and |
13:50 | Sequence and structural features that control aggregation into amyloid Sheena Radford Astbury Centre for Structural Molecular Biology, University of Leeds, United Kingdom |
POSTER PRIZE AWARD | |
14:40 | Poster prizes sponsored by Alzheimer Forschung Initiative e.V. |
14:50 | Closing remarks Inga Kadisha, Thomas van Groenb and Dieter Willboldc (organizing committee) aHeersink School of Medicine, Dept. Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, USA |
The Symposium is generously supported by Alzheimer Forschung Initiative e.V. and Joachim Herz Stiftung.